Valuation: PAVmed Inc.

Capitalization 14.88M 12.86M 11.65M 11.18M 20.4M 1.37B 21.3M 138M 55.07M 654M 55.83M 54.64M 2.35B P/E ratio 2025 *
-2.89x
P/E ratio 2026 * -0.43x
Enterprise value 14.88M 12.86M 11.65M 11.18M 20.4M 1.37B 21.3M 138M 55.07M 654M 55.83M 54.64M 2.35B EV / Sales 2025 *
-
EV / Sales 2026 * 29.8x
Free-Float
90.91%
Yield 2025 *
-
Yield 2026 * -
1 day-1.83%
1 week-1.69%
Current month-1.69%
1 month-8.24%
3 months-4.69%
6 months-22.98%
Current year+49.61%
1 week 9.3
Extreme 9.2987
10.63
1 month 8.43
Extreme 8.43
11.34
Current year 6
Extreme 6
28.44
1 year 6
Extreme 6
28.44
3 years 6
Extreme 6
280.91
5 years 6
Extreme 6
4,365
10 years 6
Extreme 6
6,858
Manager TitleAgeSince
Compliance Officer 62 2023-03-31
Chief Executive Officer 60 2014-06-25
Director of Finance/CFO 69 2017-03-20
Director TitleAgeSince
Director/Board Member 60 2014-09-30
Chairman 60 2014-06-25
Director/Board Member 71 2014-12-31
Change 5d. change 1-year change 3-years change Capi.($)
-1.83%-1.69%-50.70%-95.36% 14.88M
-2.79%-2.31%-3.52%-8.85% 193B
-3.29%-4.30%-10.53%+105.18% 176B
-2.25%-5.90%-7.73%-20.67% 143B
-2.05%-5.98%-28.32%+51.35% 108B
+0.07%-3.87%-23.13%-20.00% 52.25B
-3.40%-5.47%+13.84%+3.73% 48.72B
-2.05%-2.62%+10.90%+13.87% 37.19B
-3.03%-11.13%-12.32%-2.33% 35.14B
-2.02%-4.64%-8.53%-19.19% 33.38B
Average -2.17%-1.74%-12.00%+0.77% 82.7B
Weighted average by Cap. -2.42%-1.88%-9.13%+22.23%

Financials

2025 *2026 *
Net sales - 500K 432K 392K 376K 686K 45.92M 716K 4.63M 1.85M 22M 1.88M 1.84M 78.89M
Net income -7.1M -6.14M -5.56M -5.34M -9.74M -652M -10.17M -65.78M -26.29M -312M -26.65M -26.08M -1.12B -20.4M -17.64M -15.98M -15.34M -27.97M -1.87B -29.21M -189M -75.52M -898M -76.57M -74.93M -3.22B
Net Debt - -
Logo PAVmed Inc.
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Employees
39
Date Price Change Volume
26-03-06 9.910 $ -4.80% 1,124
26-03-05 10.41 $ -0.86% 17,471
26-03-04 10.50 $ +3.45% 40,981
26-03-03 10.15 $ +0.89% 36,962
26-03-02 10.06 $ -0.20% 8,408
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
10.41USD
Average target price
510.00USD
Spread / Average Target
+4,799.14%

Quarterly revenue - Rate of surprise